Advertisement

Topics

Biothera enters into immuno-oncology clinical trial collaboration with AstraZeneca

10:20 EDT 6 Sep 2018 | Pharmaceutical Business Review

Imprime PGG is an innate immune trigger that activates anti-cancer T cells.  Durvalumab is a human monocolonal antibody that blocks the immune checkpoint protein, programmed death-ligand (PD-L1), and

The post Biothera enters into immuno-oncology clinical trial collaboration with AstraZeneca appeared first on Pharma Business review.

Original Article: Biothera enters into immuno-oncology clinical trial collaboration with AstraZeneca

NEXT ARTICLE

More From BioPortfolio on "Biothera enters into immuno-oncology clinical trial collaboration with AstraZeneca"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...